Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX02 vs Herceptin in HER2+ Metastatic Breast Cancer
NCT03084237Phase 3Completed
- Sponsor
- Henlius
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Henlius. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03084237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084237.